Aktis Oncology, Inc. Research and Development Expense
Aktis Oncology, Inc. (AKTS) reported Research and Development Expense of $25.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Aktis Oncology, Inc. research and development expense for the quarter ending 2026-06-30 was $25.28M, a 35.71% increase year-over-year.
- Aktis Oncology, Inc. research and development expense for the quarter ending 2026-03-31 was $20.04M, a 26.31% increase year-over-year.
- Aktis Oncology, Inc. research and development expense for the quarter ending 2025-06-30 was $18.63M.
- Aktis Oncology, Inc. research and development expense for the quarter ending 2025-03-31 was $15.86M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $25.28M 10-Q · filed 2026-08-13 | $45.32M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $20.04M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $18.63M 10-Q · filed 2026-08-13 | $34.49M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $15.86M 10-Q · filed 2026-05-11 |